Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 208
- Registration Number
- NCT06707194
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Nan Fang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Application of N-of-1 Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT06016517
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-11-19
- Target Recruit Count
- 60
- Registration Number
- NCT06011889
- Locations
- 🇵🇱
Centrum Wsparcia Badań Klinicznych, Warsaw, Mazowieckie, Poland
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05281614
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Benaroya Research Institute, Seattle, Washington, United States
Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- OptiSkin Medical
- Target Recruit Count
- 10
- Registration Number
- NCT05135312
- Locations
- 🇺🇸
OptiSkin Medical, New York, New York, United States
A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04973566
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 583
- Registration Number
- NCT04582084
- Locations
- 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Connective Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran, Islamic Republic of
🇮🇷Hafez Hospital, Shiraz, Fars, Iran, Islamic Republic of
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 763
- Registration Number
- NCT04507763
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.